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cardiovascular disease (CVD) is one of the leading causes of deathworldwide, accounting for 16･7million
deathSper annunaccording tothe World HealthOrganiZation･ CVD encompasses a wide spectrum of cardiac pa-
thologleSincluding 5･3 million people living withheart鮎lure inthe USAaloneandthis value is expected to dou-
II
ble bythe year2030 asthe Hbaby boomer generation ages･ Heart failure develops as a result of prolonged stress
which canbe caused by numerous conditions including myocardialinfarction, Valve defectsand hypertcnsion･
These conditions initially placethc heartunder stress which induces adaptive cardiac hypertrophy･ However･ over
timethe stress leads to maladaptive hypertrophy, ventricular dilationand contractile impalrmentS Such as systolic
dysfunction. Althoughmuch effort has been directed toward understandingthe mechanismunderlying heart failure
progressionand developingtherapeutic approaches to treat and/or prevent heart failure･there still is no cure avail-
able. Because of limitation of currenttherapies for heart failure,the mortality for heart failure patients is extremely
highwithpatients only having a 50% chance of surviving 3 to 5 years aRer diagnosis･ Therefore, additionalstudies
are required to increaseunderstanding of the therapeutic targetsandthe signals involved in loss of cardiac function
during progression of heart failure･ The main achievements of my research are summarized below･
l･ TargetiJIg Akt for cardioprotection by vanadium compounds on myocardiAI ischemi&/reperfusion-in-
duced injury. ln the cardiovascular system, Akt,also named protein kinasc B plays criticalroles in the regula-
tion of cardiac hypcrtrophy,anglOgeneSis, and apoptosis･ Firstly, I found that Akt signaling lS SigniGcantly im-
paired in rat heartfollowing myocardialischemia-reperfusion (MIR) injury withconcomitant deregulation of the
downstreamAkt pathways. To rescue heart &om MIR-induced injury and contractile dysfunction, I introduced a
novel Akt activator, his(1-oxy-2-
pyridinethiolato)oxovanadium (IV)
lVO(OPT)]･ The VO(OPT) ad甲inis-
tration in MIR model rats upregulated
Akt sigrLaling in the cardiomyocytes
and significantly reducedthe isch-
emia-induced infarction (Fig. I ). Akt
activation induced phosphorylation
of proapoptotic protein Bad, thereby
reducing mitochondria-dependent
apoptosis. Moreover, VO(OPT) treat-
ment abolished dephosphorylation of
forkhead transcrlPtlOn factors after
Fig. I : Pubtiye mechmism ol myocJLrdjd protection by VO(OPT)･
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ischemia/reperfusion injury,thereby inhibiting expressiorL Of Fas ligandand Bin. Furthermore, VO(OPT) treatment
a鮎r ischemia/reperfusion promoted expression of FLIPthrough Akt activation,thereby Mer inhibiting activation
of Fas/Fas-ligand intracellularsignal(Fig. 1). Taken together, VO(OPT) treatment during ischemia/reperfusion is
likely beneficial as a cardioprotective drug in,subjectsundergolng rePerfusiontherapy following a myOCardialin-
farction.
2･ A hovel r如model of postmenoptLSA1 myocArdial hypertrophywith iJnPired Akt-mediated eNOS sigAaI-
IJlg. Secondly, I documentedthatthe pathologiCalhypertrophy induced by pressure overload causes aninactivation
ofAkt signaling inthe heart･ I introduced a novel heart injury model using ovriectomized (OVX)and pressure
overloaded (PO) female rats, which is attractive model for testing cardioprotective drugs in hypertension-induced
cardiac injury ln POStmenOPauSalwomen. Using this model, I confirmedthat ovariectomy aggravates pressure over-
load-induced hypertrophy. The cardiac Injuries in OVX-PO rats were associated withimpalrmentS Of both Aktand
Akt-mediated eNOS signaling pathways (Fig. 2). Interestingly, rats subjected to OVX-PO wereunable to compen-
sate cardiac dysfunction following hypertrophy,thereby increasing mortality following repeated injection of isopro-
terenol. To confirmthe causative role of impaired Akt-mediated eNOS signaling in OVX-PO-induced cardiomy-
opathy,the OVX-PO rats were administered withVO(OPT) for two weeks after OVX-PO surgery. The VO(OPT)
administration significantly restoredthe reduced Akt activity and increased Akt-mediated eNOS activation (Fig. 2).
The VO(OPT)-induced eNOS activa-
tionalsoameliorated le氏 ventricular
(LV) contractile dysfunction,thereby
reducing mortality following repeated
Injection of isoproterenol. Taken to-
gether, Akt.-mediated eNOS activation
by VO(OPT) administration is critical
to rescue heart f110m PO-induced hy-
pertrophy in ovariectomized rats and
preventsthe progression of hypertro-
phy to heart failure.
3. Sigm&-I recepto｢Jnedhted &cti-
yati011 0I Akt-eNOS signaling a血e-
Iior&teS preSstlre OYerlo&d-indlJCed
bypertrophy And dysfutLCtion.














Fig. 2: PtLbtiye meChAiszb Of posttbeAOPtLSAl hypertrophy &JLd
cArdioprotecdye &ctioJ1 0E VO(OPT)
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expressed as integralmembrane protein withtwo transmembrane domains. The physiologlCal relevance of the enig-
matic Sig-lR in heart remainsuncleaT. To clarifythe physiologicaland pathologicalrole of Sig-lR onthe hear(
function, Ⅰfirst observedthe expression of Sis-lR in normal rat heart and also in pathologiCalcondition, mainly
PO-induced hypertrophy in OVX rats. I demonstrated, forthefirst time, the potentialrole of Sig-1 R expressionin
the heart to attenuate P0-induced hypertrophy in OVX rats. Sis-lR expression decreased time dependently along
with progression of cardiac hypertrophy with significant decreased expression observed 4 weeks after OVX-PO.
To confi-the cardioprotective role of Sis-lR onthe heart against PO-induced hypertrophy, I treatedthe rats with
the endogenous ligands for Sig-1 R. Neurosteroid dehydroepiandrosterone (DHEA),alsoknown as Sig-I R agonist,
elicited Sis-I R upregulationand stimulated Sis-1 R-mediated activation of the Akt-eNOS signaling in hypertroI
phied cardiomyocytes in OVX-PO rats (Fig. 3). Moreover, DHEA could protect the kidneyand aortic endothelial
cells via stimulation of the Akt signaling pathway. Thus, as Akt signaling is dovmstream of Sis-lR, Sis-1 R--medi-
ated eNOS activation is essential to attenuate PO-induced cardiac hypertrophy and injury (Fig. 3).






Fig･ 3: ScheJnatic presentation oI DHEA一mediated mechnisms oI cardioprotectioJl through Sigm8-I recep-
tor
In summary, I proposed novel mechanisms of detrimentalcardiac remodelingthroughAkt downregulation, which
accounts for cardiac decompensation in MIR- and PO-induced cardiac injuries. I also provided a noveltherapeutic
strategy for ischemia-and hypertension-induced cardiac injuries by rescuing Akt signaling by VO(OPT)and el-
evating Sis-1R/Akt signaling by DHEA. Finally, OVX-POfemale rats are attractive model to testtherapeutics for
cardiovascular events especially in postmenopausalwomen.
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審査結果の要旨
循環器障害である高血圧,狭心症,不整脈などに対する有効な治療薬が開発されているにも拘らず,
心臓疾患は全世界において死亡原因のトップである｡特に,心臓肥大から心不全に進展するメカニズム
の解明と致死的な心不全の治療法は未だ確立されていない｡従って,心不全進展のメカニズムと治療薬
の開発が重篤な心臓疾患を持つ患者の治療とQOLを高めるために必要である｡本研究では1)冠状動脈
の虚血再潜流ラットを用いて新規心臓保護薬バナジウム有機錯体の心筋保護作用とそのメカニズムを明
らかにした｡ 2)卵巣摘出雌性ラットを用いて,圧負荷による心筋障害にproteinkinaseB (Akt)と内皮型
一酸化窒素合成酵素(eNOS)の機能低下が関わることを明らかにした｡ 3)卵巣摘出圧負荷雌性ラットに
おける心筋障害に対してsigma-1受容体のアゴニストが有効な治療薬となることを明らかにしたo
Aktは種々細胞の生存に必須の働きをしている｡ Bhuiyan氏は心筋梗塞ラットの心臓でAkt活性が顕著
に減少すること,その結果Aktにより活性化されるeNOSの障害が起こることを明らかにした｡本研究
はバナジウム有機錯体が心臓においてAktを活性化してeNOS障害を抑制すること,同時に,心筋の梗
塞サイズも有意に縮小することを証明した.次に,閉経後の女性での高血圧による循環器障害のメカニ
ズムについて卵巣摘出圧負荷雌性ラットを用いて明らかにした｡心筋梗塞モデルラットと同様に, Akt
とeNOSの機能低下が心筋障害に深く関わっていた｡さらに, sigma-1受容体のダウンレギュレーショ
ンも心機能障害に関わるという新しい知見も報告した｡老化抑制ホルモンであるdehy血oepiandrosterone
(DHEA)がsigma-1受容体刺激作用を介して,卵巣摘出雌性ラットの圧負荷による心機能障害を完全に
回復させることを証明した｡ Bhuiyan氏の研究は心不全-の進展を抑制する新しいリード化合物を創出
したことに加えて,心疾患治療薬開発における新規創薬ターゲットとして, sigma-1受容体を世界で初
めて見出した点で大いに評価できる｡
よって,本論文は博士(薬学)の学位論文として合格と認める｡
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